TLX (Telix Pharmaceuticals) Short Ratio


TLX Telix Pharmaceuticals Ltd TLX
50 GF Score
Price $12.15
GF Value $29.70
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Telix Pharmaceuticals Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

TLX
50GF Score
Telix Pharmaceuticals Ltd TLX
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Telix Pharmaceuticals (TLX) Overvalued in 2026?

Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued. The current stock price of $12.15 is trading 59.1% below its estimated GF Value™ of $29.70. GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TLX:

  • Short Ratio:
  • GF Value™: $29.70 vs. price of $12.15 (59.1% below fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Telix Pharmaceuticals Business Description

Address 55 Flemington Road, Level 4, North Melbourne, Melbourne, VIC, AUS, 3051
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
50GF Score

Get the complete analysis for TLX

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.15
Price
$29.70
GF Value